Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target
Alkermes Analyst Ratings
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
JMP Securities Reiterates Market Outperform on GH Research, Maintains $39 Price Target
GH Research Analyst Ratings
GH Research Shares Are Trading Lower. The Company Reported Q2 Financial Results and Appointed a New CEO.
GH Research Q2 2024 GAAP EPADS $(0.20) Beats $(0.23) Estimate, Cash Balance Of $204.5M
ADVISORSHARES PSYCHEDELICS ETF To Carry Out 1-for-10 Reverse Stock Split On September 10th, 2024
September 2nd (Eastern Time) - $ADVISORSHARES PSYCHEDELICS ETF(PSIL.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from
Compass Therapeutics Files $300M Mixed Securities Shelf
AdvisorShares Announces 1-For-10 Reverse Split Of ETF, Effective September 10, 2024
HC Wainwright & Co. Maintains Buy on Mind Medicine, Raises Price Target to $55
Mind Medicine Analyst Ratings
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Trials for Psychedelic Drug Candidate for PTSD Under Scrutiny by FDA - Report
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target
Clearmind Medicine Shares Are Trading Higher After the Company Announced It Received a Patent Approval From the US Patent and Trademark Office.